What Is AbbVie Inc. (ABBV) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, the balance of valuation evidence tilts cautious on AbbVie Inc. at its current price of $248.05. The composite intrinsic value is estimated at $252.30 (+1.7% average return), with 8 models flagging overvaluation risk. Notably, Markov DDM sees the most upside at +265.6% (fair value: $906.99), while Regime Cross is the most conservative at -92.3% ($19.13). The spread between these extremes — +357.9% — reveals how different analytical frameworks can reach starkly different conclusions. Among models with highest confidence, EPV lean bearish — adding weight to the bearish side of the thesis.
What Do the Models Say About ABBV?
12 of 13 models are currently active for ABBV. Of these, 4 models suggest upside while 8 models suggest overvaluation. The Bayesian DCF estimates ABBV's intrinsic value at $434.49, implying +75.2% upside from the current price. See which stocks rank higher →
How Does ABBV Rank in Drug Manufacturers - General?
Among 3 Drug Manufacturers - General stocks, ABBV ranks #2 by Quality of Company score. CirclFi's QOC score of 7.6/10 evaluates 32 fundamental signals. A score of 7.6 indicates above-average quality.
Within the Drug Manufacturers - General space, AbbVie Inc. competes in an environment where biosimilar competition timeline often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.
Is ABBV a Value Trap?
CirclFi's Value Trap algorithm assigns ABBV a score of 13/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
12 of 13 models are active for AbbVie Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Quality of Company (QOC) framework, which evaluates 32 signals including margin stability, revenue growth trajectory, leverage, and free cash flow generation, AbbVie Inc. is rated at 7.6/10. This strong-tier score demonstrates strong fundamentals across the majority of our quality signals.
The gap between the most bullish and bearish model spans +357.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ABBV valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ABBV's 12 active models, average confidence is 45%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad